A study suggests that patients with wet AMD may regain vision through a novel approach — removing abnormal blood vessels and ...

The cause of age-related macular degeneration can be varied and symptoms are often not recognized immediately, according to ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Telomir Pharmaceuticals shared results from its recent preclinical studies conducted in human retinal cell lines and plans ...

Optical Coherence Tomography (OCT) provides detailed images of the back of your eye without causing any discomfort. The ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...

Baseline angiographic lesion characteristics predictive of clinical responsePublished in peer-reviewed journal Ophthalmic Surgery, Lasers and ...

Retinal Biologics MarketThe Retinal Biologics Market generated USD 19.96 billion in revenue in 2021 and is projected to grow to USD 41.92 billion by 2028, expanding at a CAGR of 11.1% from 2022 to ...

AMD affects a small region of the retina — the light-sensing tissue at the back of the eye — called the macula, which is responsible for our detailed central vision. After about the age of 50 ...

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population.

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...

AI in combination with OCT and fundus photography helped to diagnose and treat AMD in a variety of studies. AI’s efficacy is limited by insufficient or unbalanced data and limited generalizability.